«Fersikard kids» preparatining yangi tug‘ilgan chaqaloqlarda asoratli kechuvchi endotoksikozni davolashdagi samaradorligi

Endotoxicosis in newborns is a systemic pathological syndrome that develops due to the circulation of bacterial endotoxins and inflammatory mediators and is accompanied by pronounced disturbances of microcirculation, metabolism, and hemodynamics. Despite the introduction of modern intensive care protocols, the complicated course of endotoxicosis with the development of multiple organ failure remains a significant cause of neonatal morbidity and mortality. This study aimed to evaluate the clinical efficacy and safety of the drug “Fersicard Kids” as part of combination therapy for complicated endotoxicosis in newborns. A prospective randomized controlled trial was conducted involving 84 patients with grade II–III endotoxicosis. The main group received standard therapy in combination with the drug “Fersicard Kids” at a dosage of 1 ml/kg/day administered intravenously for 7 days, while the control group received standard therapy only. A significant decrease in the levels of C-reactive protein, procalcitonin, lactate, and medium-weight molecules, as well as a reduction in the duration of respiratory support and the frequency of multiple organ failure, was observed in the main group (p < 0.05). No adverse reactions were registered. The obtained data indicate the feasibility of including this drug in the combination therapy of complicated endotoxicosis in newborns.

Hali tarjima qilinmagan